Navigation Links
Amgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
Date:7/26/2012

growth.
  • XGEVA sales increased 17 percent on a sequential basis, reflecting increased segment share as well as growth in the overall skeletal-related events segment.
  • Prolia sales increased 36 percent on a sequential basis, reflecting continued unit growth globally.

  • Product Sales Detail by Product and Geographic Region$Millions, except percentagesQ2 '12Q2 '11YOY ΔUSROWTOTALTOTALTOTALNeulasta®/ NEUPOGEN®$1,062

    $285

    $1,347$1,3262%Neulasta®794

    221

    1,0151,0150%NEUPOGEN®268

    64

    3323117%Enbrel®991

    67

    1,05895611%Aranesp®215

    321

    536585(8%)EPOGEN®525

    0

    525543(3%)Sensipar® / Mimpara®150

    82

    23219917%Vectibix®31

    59

    908111%Nplate®50

    36

    867515%XGEVA®156

    23

    17973*Prolia®75

    45

    12044*Other 0

    27

    2711*Total product sales$3,255

    $945

    $4,200$3,8938%* Not meaningfulOther Revenues

  • Other revenues increased to $277 million in the second quarter of 2012 versus $66 million in the second quarter of 2011, driven by changes to the Company's motesanib collaboration with Takeda Pharmaceutical Company Limited.  As part of efforts to focus its research and development (R&D) activities, in the second quarter, the Company replaced the global co-development and profit share agreement with an exclusive license for Takeda to develop, manufacture and commercialize motesanib.  This resulted in revenue recognition of $206 million from an upfront payment received from Takeda when the collaboration was originally formed in 2008.
  • Operating Expense and Tax Rate Analysis, on an Adjusted Basis

  • Cost of Sal
    '/>"/>

  • SOURCE Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
    2. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    3. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    4. The Female Health Company Reports Second Quarter Operating Results
    5. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
    6. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
    7. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    8. Elsevier Launches Second Annual Mosbys Superheroes of Nursing Contest During Nurses Week 2012
    9. BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti
    10. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
    11. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... 2015 RnRMarketResearch.com adds Syringes ... report that provides an overview of syringes and ... from in-house databases, secondary and primary research. ... products pipeline spread across 124 pages, talking about ... and 5 figures is now available at ...
    (Date:7/31/2015)... According to a new market research ... Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), ... Global Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment ... 2020, at a CAGR of 7.6%.from 2015 to 2020. ... T ables and 37 F ...
    (Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
    Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
    ... Share the hope." With these words, Lilly USA, LLC, ... the 2010 Oncology On Canvas: Expressions of a Cancer ... biennial competition invites residents of the United States and Puerto ... members, friends, caregivers and healthcare providers - to express, through ...
    ... Inc. (Nasdaq: OREX ), a biopharmaceutical company focused ... results for the three months ended September 30, 2009. ... , As of September 30, 2009, Orexigen held ... additional $50.9 million in investment securities, available-for-sale. Together, ...
    Cached Medicine Technology:Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 2Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 3Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 4Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 5Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
    (Date:7/31/2015)... ... July 31, 2015 , ... Mullin/Ashley Associates , ... the 2015 Aster Awards national competition for a marketing communications campaign created for ... surrounding communities in Coastal Maryland and Southern Delaware. , A Bronze Award was ...
    (Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
    (Date:7/31/2015)... ... July 31, 2015 , ... ... – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports ... , Instead of risking containment — or even destruction — of products, an ...
    (Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... patients using the RenovoCath,™ a novel catheter that was developed for targeted delivery ... pancreatic cancer are now being treated at Florida Hospital Tampa with the device ...
    (Date:7/31/2015)... ... ... Ticket Down is a reputable source of authentic USA vs. Australia tickets ... the Australia Women's National Team in two separate friendly contests. The first match ... second match will occur in Birmingham, Alabama at Legion Field. These friendly international ...
    Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
    ... has found that major surgeries and operations could prove deadly ... showed that elderly men with even slightly irregular red blood ... major surgery. ,The study, which examined data from ... to demonstrate that even minor anaemia or polycythemia, when the ...
    ... the wrappers of the diabetes drug Avandia will soon start ... congestive heart failure . ,Some of the experts, ... that the delay in implementation is an example of industry ... ,GlaxoSmithKline's Avandia has been in use since 1999. The ...
    ... number of panthers is slowly on the rise . ... estimates of the census figures indicated an increase in the ... to the 2004 wildlife census, there were over 550 panthers ... Park, has the maximum number at 83. At least 15 ...
    ... Bean will soon be available in the South Asian markets, ... licensing agent for India, Pakistan, Bangladesh and Nepal has inked ... popular character portrayed by Rowan Atkinson to the South Asia ... the television producer of the popular comedy series Mr. Bean. ...
    ... keep children as safe as possible in cars, leaving parents ... major review of restraint legislation, accident statistics and parent surveys ... graduate to an adult seatbelt without the use of ... or about 11 years old, and that children under 12 ...
    ... Taking serious note of doctors using advertisements to lure ... Monday asked the state's medical council to take steps ... education and research minister Tikshan Sood said here that ... but also a violation of the Medical Council Act. ...
    Cached Medicine News:Health News:Major Surgeries and Operations Could Prove Deadly for Anaemic Older Men 2Health News:Child Car Seat Danger 2
    Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
    ... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
    ... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
    ... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
    Medicine Products: